


## Asco 2022 - a novel target rounds out Daiichi's triple



Jacob Plieth

Did Daiichi Sankyo's antibody-drug conjugates win Asco? Data on the Japanese group's [Her3-targeted patritumab deruxtecan](#) served as a prelude to [Enhertu's practice-changing Destiny Breast04 result](#), widely acclaimed as the most important dataset of this year's meeting. For an encore, Daiichi today presented the first human data on DS-6000, an ADC targeting CDH6, which could help validate this mechanism. CDH6, or human cadherin-6, is a protein thought to be overexpressed in ovarian and renal cell cancers. A [phase 1 study](#) yielded 20 evaluable patients at a February data cutoff, six of whom have developed partial remissions, Asco heard. Two are unconfirmed, however; of the four confirmed three were in platinum-resistant ovarian cancer. There were some dose-limiting toxicities, and one high-dose patient discontinued because of pneumonitis. Though retrospective analysis of patients' CDH6 expression has yet to be performed, these early data give some hope in a highly refractory population for a new target that has no other clinical-stage assets in the competitor pipeline, according to *Evaluate Pharma*. Daiichi told *Evaluate Vantage* that DS-6000 was "one of our rising stars", and said the approach differed from that taken by [Novartis's HKT288, an anti-CDH6 ADC scuppered by toxicity not long ago](#).



Source: Dr Erika Hamilton & Asco.

### More from Evaluate Vantage

Evaluate HQ  
44-(0)20-7377-0800

Evaluate Americas  
+1-617-573-9450

Evaluate APAC  
+81-(0)80-1164-4754

© Copyright 2022 Evaluate Ltd.